DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-861 in Participants With Narcolepsy Type 2

Phase 2

Completed

Conditions: Narcolepsy Type 2

Interventions: Drug: Placebo
Drug: TAK-861 2 mg
Drug: TAK-861 2 mg and 5 mg

First Posted Date: 2023-01-18

Last Posted Date: 2025-01-09

Lead Sponsor: Takeda

Target Recruit Count: 71

Registration Number: NCT05687916

Locations: 🇺🇸
SDS Clinical Trials, Inc., Santa Ana, California, United States
🇺🇸
Ohio Sleep Medicine Institute, Dublin, Ohio, United States
🇺🇸
Stanford Center for Sleep Sciences and Medicine, Redwood City, California, United States

and more 53 locations

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Phase 3

Recruiting

Conditions: Alpha1-Antitrypsin Deficiency

Interventions: Other: Placebo
Drug: Fazirsiran Injection

First Posted Date: 2023-01-10

Last Posted Date: 2025-04-29

Lead Sponsor: Takeda

Target Recruit Count: 160

Registration Number: NCT05677971

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States

and more 72 locations

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Phase 2

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2023-01-06

Last Posted Date: 2025-01-27

Lead Sponsor: Takeda

Target Recruit Count: 52

Registration Number: NCT05673785

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
The First Hospital of Jilin University, Changchun, China

and more 13 locations

A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion

Not yet recruiting

Conditions: Gaucher Disease

First Posted Date: 2023-01-03

Last Posted Date: 2025-04-18

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT05669729

A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Active, not recruiting

Conditions: Crohn's Disease
Ulcerative Colitis

Interventions: Other: No Intervention

First Posted Date: 2022-11-23

Last Posted Date: 2025-03-27

Lead Sponsor: Takeda

Target Recruit Count: 1006

Registration Number: NCT05626088

Locations: 🇧🇷
Pesquisare Saúde S/S Ltda, Santo André, São Paulo, Brazil

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Soticlestat 300 mg
Drug: Soticlestat 600 mg
Drug: Soticlestat 900 mg
Drug: Alprazolam
Drug: Placebo

First Posted Date: 2022-11-02

Last Posted Date: 2024-12-09

Lead Sponsor: Takeda

Target Recruit Count: 100

Registration Number: NCT05602818

Locations: 🇺🇸
Altasciences, Overland Park, Kansas, United States

A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)

Completed

Conditions: Inflammatory Bowel Disease (IBD)
Ulcerative Colitis
Crohn's Disease

First Posted Date: 2022-10-27

Last Posted Date: 2023-01-19

Lead Sponsor: Takeda

Target Recruit Count: 423

Registration Number: NCT05596422

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Chang Gung Memorial Hospital-Linkou, Taoyuan, Taiwan

and more 1 locations

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Modakafusp Alfa
Drug: Daratumumab

First Posted Date: 2022-10-21

Last Posted Date: 2024-04-03

Lead Sponsor: Takeda

Target Recruit Count: 58

Registration Number: NCT05590377

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division), Overland Park, Kansas, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne, Indiana, United States

and more 24 locations

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

Phase 3

Recruiting

Conditions: Von Willebrand Disease (VWD)

Interventions: Biological: Vonicog Alfa
Biological: ADVATE

First Posted Date: 2022-10-17

Last Posted Date: 2025-03-12

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT05582993

Locations: 🇮🇹
Azienda Ospedaliera Pediatrica Santobono Pausillipon, Napoli, Italy
🇮🇹
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin (Torino), Italy
🇺🇸
Childrens Hospital of Michigan, Detroit, Michigan, United States

and more 7 locations

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada

Completed

Conditions: Cytomegalovirus (CMV)

First Posted Date: 2022-10-13

Last Posted Date: 2024-04-25

Lead Sponsor: Takeda

Target Recruit Count: 159

Registration Number: NCT05576805

Locations: 🇦🇹
MU Graz, Graz, Austria
🇦🇹
MU Innsbruck, Innsbruck, Austria
🇮🇹
U Parma, Parma, Italy

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy